Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease

Abstract

IntroductionLorlatinib, a potent, selective third-generation ALK tyrosine kinase inhibitor (TKI), exhibited overall and intracranial antitumor activity in patients with ALK-positive NSCLC. MethodsRetrospective analyses in the ongoing phase 2 trial (NCT01970865) investigated the clinical benefit of continuing lorlatinib beyond progressive disease (LBPD). Patients with previous crizotinib treatment as the only ALK TKI were group A (n = 28); those with at least one previous second-generation ALK TKIs were group B (n = 74). LBPD was defined as greater than 3 weeks of lorlatinib treatment after investigator-assessed progressive disease. Only patients with the best overall response of complete or partial response or stable disease were included. ResultsThere were no major differences in baseline characteristics between groups. The median duration of treatment for patients who continued LBPD was 32.4 months (group A) and 16.4 months (group B) versus 12.5 months (group A) and 7.7 months (group B) for patients who did not continue LBPD. The median overall survival in group A was not reached (NR) in patients who continued LBPD versus 24.4 months (95% confidence interval [CI]: 12.1–NR); group B’s median was 26.5 months (95% CI: 18.7–35.5) in patients who continued LBPD versus 14.7 months (95% CI: 9.3–38.5) in patients who did not continue LBPD. The median overall survival postprogression for groups A and B was NR (95% CI: 21.4–NR) and 14.6 months (95% CI: 11.2–19.2) in patients who continued LBPD and 8.0 months (95% CI: 1.5–NR) versus 5.3 months (95% CI: 2.8–14.3) in patients who did not continue LBPD. ConclusionsContinuing LBPD is a viable treatment strategy for select patients with ALK-positive NSCLC who progressed on lorlatinib.